Clene Inc. Share Price & Technical Analysis
CLNN · $6.70 (-1.62%)
Consumer Defensive / Packaged Foods
$6.70
-1.62%
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral s…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
8% return in May, -5% avg return in past 3 year May month.
30% return in 2026, 1% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -29% | 27% | -2% | 27% | 8% | – | – | – | – | – | – | – | 30% |
| 25 | -15% | 2% | -30% | -3% | 7% | 22% | -15% | 51% | 11% | 112% | -18% | -43% | 81% |
| 24 | 63% | -18% | 2% | 0% | -21% | 6% | -36% | 15% | -13% | 37% | -34% | 23% | 24% |
| 23 | 51% | -19% | -11% | -14% | 0% | -12% | -12% | -4% | -34% | -25% | 13% | -33% | -101% |
| 22 | -30% | 6% | 30% | -34% | -22% | 12% | 33% | -10% | -6% | -44% | 6% | -7% | -65% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$70.08M
P/E ratio
—
52W high
$13.50
52W low
$2.36
Volume
1,07,160
Beta
0.89
Related stocks in Consumer Defensive
Coca-cola Co Cedears Eac…
₹23,280
Procter & Gamble Co Cede…
₹14,130
Sysco Corp Cedear Each 8…
₹13,410
Pepsico Inc Cedear Each …
₹12,260
Walmart Inc Cedear Each …
₹10,460
Frequently asked questions
- What is Clene Inc. share price today?
- Clene Inc. (CLNN) last traded around $6.70 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CLNN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CLNN. Download the app for real-time alerts.
- How can I analyze Clene Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.